Home
About Us
Membership
Member Biography

Member Biography

Tarah Ballinger, MD

Tarah Ballinger, M.D.

Phone: (317) 944-0920, Patient issues/appointments

Faculty appointments

Vera Bradley Foundation Scholar in Breast Cancer Research, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Full member, Cancer Prevention and Control

My overarching research goal is to better understand the relationship between body composition, specifically bone and lean and fat tissue, with cancer incidence, outcomes, and side effects of cancer directed therapies, with a focus on breast cancer survivors. In particular, while a large organ system, muscle tissue is relatively underexplored in the pathogenesis of breast cancer and is affected by a large portion of our current therapies.

Effect of Rycals (ARM210) on aromatase inhibitor associated muscle weaknessIUSCC-0631

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy(POSITIVE)A221405/IBCSG48-POSITIVE

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes Olaparib Expanded TBCRC048

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.S1418/BR006

A Phase 2 Study of Neratinib with or without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer17-318

Pilot study of a mobile health strategy to improve medication adherence in breast cancer survivors receiving aromatase inhibitorsCTO-IUSCC-0715

A quality improvement project to increase knowledge and referrals to the IU breast cancer prevention programCTO-IUSCC-0718

Phase 1a/1b Trial of Exercise Treatment with Concurrent First-Line Therapy for Hormone Receptor Positive Metastatic Breast CancerCTO-TBCRC054

Exercise in Metastatic Breast cancer: EMBodyCTO-IUSCCC-0781

A pilot study examining molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early stage breast cancerIUSCC-0647

CLUSTER RANDOMIZED CONTROLLED TRIAL OF PATIENT AND PROVIDER DECISION SUPPORT TO INCREASE CHEMOPREVENTION INFORMED CHOICE AMONG WOMEN WITH ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU - MAKING INFORMED CHOICES ON INCORPORATING CHEMOPREVENTION INTO CARE (MiCHOICE)CTO-SWOG-S1904

A Phase II trial of Atezolizumab (anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast CancerTBCRC043

Understanding and Predicting Breast Cancer Events After TreatmentWF-97415

Assessing Exercise Behavior and Preferences Among Patients and Oncologists at Indiana University Simon Cancer CenterIUSCC-0690

A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive, HER2-positive breast cancer (ADEPT) CTO-20-347

Identifying gaps in breast cancer interception for high-risk women within IU HealthCTO-IUSCCC-0818

Examining Genetic Ancestry, Allostatic Load and Treatment Completion among Patients with Breast CancerCTO-2022C0174

Targeted Prevention of Postpartum-Related Breast CancerCTO-MC220301

A RANDOMIZED PHASE III TRIAL COMPARING ACTIVE SYMPTOM MONITORING PLUS PATIENT EDUCATION VERSUS PATIENT EDUCATION ALONE TO IMPROVE PERSISTENCE WITH ENDOCRINE THERAPY IN YOUNG WOMEN WITH STAGE I-III BREAST CANCER (ASPEN)CTO-S2010

Headlines & highlights

#ResearchCuresCancer

Support Our Research